IGF1R and cancer: Based on our finding, we suggest that heterodimerization of NLG IGF1R with IR in cancer cells may be a potential biomarker for predicting figitumumab sensitivity because cancer cells expressing more functional membrane-bound IGF1R/IR HRs that bind IGF1 ligands were more sensitive to treatment with anti-IGF1R antibody.